Two routes to overeating are discussed; they are both premised on people's strong motivation to avoid eating excessively and thereby avoid negative ascriptions associated with the overeatingloverweight stereotype. The first route to overeating involves infractions of restrictive intake norms: people who attempt to restrict their intake by implementing dietary rules often run afoul of disinhibit...

The size and shape of organs are characteristic for each species. Even when organisms develop to different sizes due to varying environmental conditions, such as nutrition, organ size follows species-specific rules of proportionality to the rest of the body, a phenomenon referred to as allometry. Therefore, for a given environment, organs stop growth at a predictable size set by the species's g...

The sample size of a statistical sample is the number of observations that constitute it. It is typically denoted n, a positive integer (natural number). Typically, all else being equal, a larger sample size leads to increased precision in estimates of various properties of the population. This can be seen in such statistical rules as the law of large numbers and the central limit theorem. Repe...

Often, sample size is not fixed by design. A key example is a sequential trial with a stopping rule, where stopping is based on what has been observed at an interim look. While such designs are used for time and cost efficiency, and hypothesis testing theory has been well developed, estimation following a sequential trial is a challenging, still controversial problem. Progress has been made in ...

Medical research has evolved conventions for choosing sample size in randomized clinical trials that rest on the theory of hypothesis testing. Bayesian statisticians have argued that trials should be designed to maximize subjective expected utility in settings of clinical interest. This perspective is compelling given a credible prior distribution on treatment response, but there is rarely cons...

In this paper, we consider two-stage designs with failure-time endpoints in single-arm phase II trials. We propose designs in which stopping rules are constructed by comparing the Bayes risk of stopping at stage I with the expected Bayes risk of continuing to stage II using both the observed data in stage I and the predicted survival data in stage II. Terminal decision rules are constructed by ...